keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast

keyword
https://www.readbyqxmd.com/read/28542378/familial-breast-cancer-genetic-counseling-over-time-including-patients%C3%A2-expectations-and-initiators-considering-the-angelina-jolie-effect
#1
Christina Evers, Christine Fischer, Nicola Dikow, Sarah Schott
PURPOSE: The German Consortium for hereditary breast/ovarian cancer (GC-HBOC) aims for nationwide access to professional, individualized yet structured care for families at high risk. The identification of such families remains key for optimal care. Our study evaluates counselees' characteristics, referral practices, expectations and motivations in respect to their first genetic consultation. The impact of the Angelina Jolie Effect (AJE) was prospectively assessed. METHODS: All counselees could participate through a questionnaire...
2017: PloS One
https://www.readbyqxmd.com/read/28536943/change-in-sonographic-brightness-can-predict-pathological-response-of-triple-negative-breast-cancer-to-neoadjuvant-chemotherapy
#2
Naoko Matsuda, Kumiko Kida, Sachiko Ohde, Koyu Suzuki, Hideko Yamauchi, Seigo Nakamura, Hiroko Tsunoda
INTRODUCTION: Ultrasound (US) is conventionally performed to determine effects of neoadjuvant chemotherapy (NAC) on breast cancer. In patients with triple-negative breast cancer (TNBC), higher pathological complete response (pCR) predicts the most favorable survival outcome. We aimed to predict pCR to NAC using echogenicity changes in US region of interest (ROI) in patients with TNBC. METHODS AND MATERIALS: We retrospectively determined clinicopathological characteristics of 52 patients with primary TNBC who underwent NAC...
May 23, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28535650/-texture-analysis-based-on-contrast-enhanced-mri-can-predict-treatment-response-to-neoadjuvant-chemotherapy-of-breast-cancer
#3
S H Sun, C W Zhou, L Y Zhao, R Z Zhang, H Ouyang
Objective: To investigate whether texture analysis based on contrast-enhanced MRI can predict pathological complete response of locally advanced breast cancer undergoing neoadjuvant chemotherapy(NAC). Methods: Forty-seven patients with breast cancer undergone neoadjuvant chemotherapy from January 2015 to February 2016 were divided into pathological complete response (pCR) group or non-pathological complete response (non-pCR) group based on surgical pathology. Their parameters of texture analysis based on MRI before neoadjuvant chemotherapy and after 2 cycles of treatment were analyzed...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28532642/optical-mammography-in-patients-with-breast-cancer-undergoing-neoadjuvant-chemotherapy-individual-clinical-response-index
#4
Pamela G Anderson, Sirishma Kalli, Angelo Sassaroli, Nishanth Krishnamurthy, Shital S Makim, Roger A Graham, Sergio Fantini
RATIONALE AND OBJECTIVES: We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxyhemoglobin ([HbO2]), deoxyhemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time points during chemotherapy. MATERIALS AND METHODS: Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on 10 patients before treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12, range: 7-18)...
May 19, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28531188/monitoring-tumor-response-to-neoadjuvant-chemotherapy-using-mri-and-18f-fdg-pet-ct-in-breast-cancer-subtypes
#5
Alexander M Th Schmitz, Suzana C Teixeira, Kenneth E Pengel, Claudette E Loo, Wouter V Vogel, Jelle Wesseling, Emiel J Th Rutgers, Renato A Valdés Olmos, Gabe S Sonke, Sjoerd Rodenhuis, Marie Jeanne T F D Vrancken Peeters, Kenneth G A Gilhuijs
PURPOSE: To explore guidelines on the use of MRI and PET/CT monitoring primary tumor response to neoadjuvant chemotherapy (NAC), taking breast cancer subtype into account. MATERIALS AND METHODS: In this prospective cohort study, 188 women were included with stages II and III breast cancer. MRI and 18F-FDG-PET/CT were acquired before and during NAC. Baseline pathology was assessed from tumor biopsy. Tumors were stratified into HER2-positive, ER-positive/HER2-negative (ER-positive), and ER-negative/PR-negative/HER2-negative (triple-negative) subtypes, and treated according to subtype...
2017: PloS One
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#6
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28526187/chemotherapy-may-eradicate-ductal-carcinoma-in-situ-dcis-but-not-the-associated-microcalcifications
#7
H Goldberg, J Zandbank, V Kent, M Leonov-Polak, A Livoff, A Chernihovsky, M Guindy, E Evron
INTRODUCTION: We studied the effect of neoadjuvant chemotherapy (NAC) ± trastuzumab on the ductal carcinoma in situ (DCIS) component in patients with locally advanced breast cancer who achieved pathological complete response (pCR). METHODS: The diagnostic biopsies of 92 consecutive breast cancer patients that were treated with neoadjuvant chemotherapy (NAC) ± trastuzumab were evaluated for the presence of DCIS. Upon completion of NAC, the surgical specimens were evaluated for complete eradication of both the invasive and non-invasive cancer in the breast...
May 4, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28525810/tumor-infiltrating-lymphocytes-in-patients-with-her2-positive-breast-cancer-treated-with-neoadjuvant-chemotherapy-plus-trastuzumab-lapatinib-or-their-combination-a-meta-analysis-of-randomized-controlled-trials
#8
REVIEW
C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, D Fumagalli, E de Azambuja, R Salgado, C Sotiriou, K Willard-Gallo, M Ignatiadis
BACKGROUND: A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the association between baseline TIL and pathologic complete response (pCR) rates in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab and lapatinib either alone or in combination...
May 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28525534/lymphocyte-density-determined-by-computational-pathology-validated-as-a-predictor-of-response-to-neoadjuvant-chemotherapy-in-breast-cancer-secondary-analysis-of-the-artemis-trial
#9
H R Ali, A Dariush, J Thomas, E Provenzano, J Dunn, L Hiller, A-L Vallier, J Abraham, T Piper, J M S Bartlett, D A Cameron, L Hayward, J D Brenton, P D P Pharoah, M Irwin, N A Walton, H M Earl, C Caldas
Background: HASH(0x42f4788) Patients and methods: HASH(0x475b8d0) Results: HASH(0x4721800) Conclusions: HASH(0x433d9e8)
May 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28524246/combined-pet-ct-and-axillary-lymph-node-marking-with-radioactive-iodine-seeds-mari-procedure-for-tailored-axillary-treatment-in-node-positive-breast-cancer-after-neoadjuvant-therapy
#10
B B Koolen, M Donker, M E Straver, M E M van der Noordaa, E J T Rutgers, R A Valdés Olmos, M J T F D Vrancken Peeters
BACKGROUND: The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND) is still the standard of care. Marking axillary lymph nodes with radioactive iodine seeds (MARI procedure) is accurate in restaging the axilla after NST (false-negative rate 7 per cent). Here, the potential of tailored axillary treatment, determined by combining the results of PET-CT before NST with those of the MARI procedure after NST, was analysed...
May 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28523352/interim-heterogeneity-changes-measured-using-entropy-texture-features-on-t2-weighted-mri-at-3-0%C3%A2-t-are-associated-with-pathological-response-to-neoadjuvant-chemotherapy-in-primary-breast-cancer
#11
Shelley Henderson, Colin Purdie, Caroline Michie, Andrew Evans, Richard Lerski, Marilyn Johnston, Sarah Vinnicombe, Alastair M Thompson
OBJECTIVES: To investigate whether interim changes in hetereogeneity (measured using entropy features) on MRI were associated with pathological residual cancer burden (RCB) at final surgery in patients receiving neoadjuvant chemotherapy (NAC) for primary breast cancer. METHODS: This was a retrospective study of 88 consenting women (age: 30-79 years). Scanning was performed on a 3.0 T MRI scanner prior to NAC (baseline) and after 2-3 cycles of treatment (interim)...
May 18, 2017: European Radiology
https://www.readbyqxmd.com/read/28521821/intratumoral-and-peritumoral-radiomics-for-the-pretreatment-prediction-of-pathological-complete-response-to-neoadjuvant-chemotherapy-based-on-breast-dce-mri
#12
Nathaniel M Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Pletcha, Anant Madabhushi
BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases...
May 18, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#13
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28509694/does-the-use-of-acellular-dermal-matrix-increase-postoperative-complications-of-the-first-stage-reconstruction-of-immediate-expander-implant-breast-reconstruction-a-matched-cohort-study
#14
Kyong-Je Woo, Jin-Woo Park, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon, Sa Ik Bang
PURPOSE: Controversy exists regarding complications associated with the use of acellular dermal matrix (ADM). This likely stems from the heterogeneous and unmatched patient characteristics in study groups. The purpose of this study was to analyze complications in a matched cohort to identify whether ADM use increased postoperative complications of the first-stage immediate expander-implant breast reconstructions. METHODS: A retrospective matched-cohort study was performed...
May 15, 2017: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/28507762/circulating-tumor-cell-clusters-associated-gene-plakoglobin-is-a-significant-prognostic-predictor-in-patients-with-breast-cancer
#15
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: Circulating tumor cells (CTCs) are linked to metastatic relapse and are regarded as a prognostic marker for human cancer. High expression of plakoglobin, a cell adhesion protein, within the primary tumor is positively associated with CTC clusters in breast cancer. In this study, we investigated the correlation between plakoglobin expression and survival of breast cancer. METHODS: We evaluated 121 breast cancer patients treated with neoadjuvant chemotherapy...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28504653/metabolic-shifts-in-residual-breast-cancer-drive-tumor-recurrence
#16
Kristina M Havas, Vladislava Milchevskaya, Ksenija Radic, Ashna Alladin, Eleni Kafkia, Marta Garcia, Jens Stolte, Bernd Klaus, Nicole Rotmensz, Toby J Gibson, Barbara Burwinkel, Andreas Schneeweiss, Giancarlo Pruneri, Kiran R Patil, Rocio Sotillo, Martin Jechlinger
Tumor recurrence is the leading cause of breast cancer-related death. Recurrences are largely driven by cancer cells that survive therapeutic intervention. This poorly understood population is referred to as minimal residual disease. Here, using mouse models that faithfully recapitulate human disease together with organoid cultures, we have demonstrated that residual cells acquire a transcriptionally distinct state from normal epithelium and primary tumors. Gene expression changes and functional characterization revealed altered lipid metabolism and elevated ROS as hallmarks of the cells that survive tumor regression...
May 15, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28503722/fertility-preservation-with-ovarian-stimulation-and-time-to-treatment-in-women-with-stage-ii-iii-breast-cancer-receiving-neoadjuvant-therapy
#17
A Jo Chien, Julia Chambers, Fiona Mcauley, Tessa Kaplan, Joseph Letourneau, Jimmy Hwang, Mi-Ok Kim, Michelle E Melisko, Hope S Rugo, Laura J Esserman, Mitchell P Rosen
PURPOSE: To determine whether fertility preservation with ovarian stimulation (OS) results in treatment delay in breast cancer (BC) patients receiving neoadjuvant therapy (NAT). METHODS: This is a retrospective study of women screened for the prospective neoadjuvant ISPY2 trial at the University of California San Francisco. All patients were <43, had stage II-III BC, and received neoadjuvant therapy. Time to initiation of NAT was compared between women who underwent OS (STIM) and women who did not (control)...
May 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28496143/serum-metabolomic-profiles-for-breast-cancer-diagnosis-grading-and-staging-by-gas-chromatography-mass-spectrometry
#18
Naila Irum Hadi, Qamar Jamal, Ayesha Iqbal, Fouzia Shaikh, Saleem Somroo, Syed Ghulam Musharraf
Detection of metabolic signature for breast cancer (BC) has the potential to improve patient prognosis. This study identified potentially significant metabolites differentiating between breast cancer patients and healthy controls to help in diagnosis, grading, staging and determination of neoadjuvant status. Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0...
May 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28495849/neoadjuvant-trials-in-er-breast-cancer-a%C3%A2-tool-for-acceleration-of-drug-development-and-discovery
#19
REVIEW
Angel L Guerrero-Zotano, Carlos L Arteaga
Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER(+)) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype...
May 11, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28488142/a-prospective-randomized-controlled-trial-of-hydrating-nail-solution-for-prevention-or-treatment-of-onycholysis-in-breast-cancer-patients-who-received-neoadjuvant-adjuvant-docetaxel-chemotherapy
#20
Ji-Yeon Kim, Oh Nam Ok, Jeong-Ju Seo, Soo-Hyeon Lee, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
PURPOSE: Onycholysis and other nail toxicities occur in approximately 20-30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients' quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAIL(®) solution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities. METHODS: This study was a prospective, randomized, controlled study of HNS for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide...
May 9, 2017: Breast Cancer Research and Treatment
keyword
keyword
72735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"